Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Conditions

Nystagmus, Congenital IdiopathicNystagmus, Acquired

Interventions

DRUG

Neramexane mesylate

2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day

Trial Locations (1)

University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester